|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30.83 USD | +2.70% |
|
+8.82% | +33.99% |
| 08-05 | Damora Therapeutics Begins Trial of DMR-001 in ET, Myelofibrosis | MT |
| 07-29 | Wedbush Adjusts Damora Therapeutics Price Target to $40 From $35, Maintains Outperform Rating | MT |
| Market Cap | 1.9B 1.64B 1.53B 1.41B 2.66B 180B 2.69B 18B 7.07B 90.29B 7.13B 6.97B 299B | P/E 2026 * |
-16.2x | P/E 2027 * | -14.9x |
|---|---|---|---|---|---|
| Enterprise Value | 1.45B 1.26B 1.17B 1.08B 2.04B 138B 2.06B 13.8B 5.42B 69.22B 5.46B 5.34B 229B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
92.38% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | +2.70% | ||
| 1 week | +8.82% | ||
| Current month | +6.35% | ||
| 1 month | +2.84% | ||
| 3 months | +23.96% | ||
| 6 months | +36.24% | ||
| Current year | +33.99% |
| 1 week | 28.42 |  | 31.77 |
| 1 month | 26.29 | | 34.89 |
| Current year | 16.5 | | 34.89 |
| 1 year | 2.45 | | 38.33 |
| 3 years | 2.01 | | 79 |
| 5 years | 2.01 | | 118.75 |
| 10 years | 2.01 | | 449.75 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jennifer Jarrett
CEO | Chief Executive Officer | 55 | 29/03/2026 |
Brian Burkavage
DFI | Director of Finance/CFO | - | 30/04/2026 |
Becker Hewes
CTO | Chief Tech/Sci/R&D Officer | 60 | 04/01/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
Peter Harwin
CHM | Chairman | 40 | 22/03/2026 |
Christopher Cain
BRD | Director/Board Member | 42 | 09/11/2025 |
Julianne Bruno
BRD | Director/Board Member | 41 | 09/11/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 06/07/26 | Sell | General Counsel | -245 | 0.0004% | ||
| 09/02/26 | Fairmount Funds Management LLC
| Fiscal year | Company | 8,713,000 | 14.4656% | |
| 09/02/26 | Fiscal year | Director | 129,000 | 0.2142% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.70% | +8.82% | +806.76% | -54.16% | 1.9B | |
| +1.03% | -0.28% | +4.25% | +15.99% | 48.57B | |
| +1.98% | +9.05% | +413.94% | +532.17% | 41.95B | |
| +3.44% | -4.65% | +28.34% | +8.81% | 38.85B | |
| +1.40% | +0.10% | +6.61% | +61.93% | 37.24B | |
| +2.42% | +5.72% | +12.38% | +44.79% | 30.67B | |
| -0.16% | -3.11% | - | - | 16.1B | |
| +2.20% | +0.48% | +34.71% | +127.15% | 16.41B | |
| +0.69% | +2.27% | +8.61% | +19.48% | 13.97B | |
| +4.25% | -8.23% | -1.49% | -35.46% | 12.62B | |
| Average | +2.00% | +0.18% | +146.01% | +80.08% | 25.83B | |
| Weighted average by Cap. | +1.92% | -0.05% | +88.78% | +119.46% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -116M -101M -94.03M -86.49M -163M -11.07B -165M -1.1B -434M -5.54B -437M -428M -18.35B | -145M -126M -117M -108M -204M -13.83B -206M -1.38B -542M -6.92B -546M -534M -22.92B |
| Net Debt | -443M -384M -357M -329M -621M -42.1B -628M -4.2B -1.65B -21.07B -1.66B -1.63B -69.77B | -326M -283M -264M -242M -458M -31.04B -463M -3.1B -1.22B -15.53B -1.23B -1.2B -51.43B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/08/26 | US$30.83 | +2.70% | 607,292 |
| 04/08/26 | US$30.02 | +5.11% | 551,119 |
| 03/08/26 | US$28.56 | -1.48% | 227,770 |
| 31/07/26 | US$28.99 | -0.75% | 314,511 |
| 30/07/26 | US$29.21 | +3.11% | 334,001 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- DMRA Stock
Select your edition
All financial news and data tailored to specific country editions
